LNA 043

Drug Profile

LNA 043

Alternative Names: LNA043

Latest Information Update: 20 Apr 2017

Price : $50

At a glance

  • Originator Novartis
  • Class Anti-inflammatories; Antirheumatics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Osteoarthritis

Most Recent Events

  • 18 Apr 2017 Phase-II clinical trials in Osteoarthritis in Austria (Intra-articular) (EudraCT2016-003418-28)
  • 01 Nov 2015 Phase-I clinical trials in Osteoarthritis in USA (Intra-articular)
  • 13 Jul 2015 Novartis plans a phase I trial for Osteoarthritis in USA (NCT02491281)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top